Newsfeeds - Spark Newswire

1 minute read

Earnings

Geron’s Earnings: A Preview

Today, 8:56 PM

Geron (NASDAQ:GERN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that Geron will report an earnings per share (EPS) of $-0.08.

GERN

3 minute read

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg

By Shanthi Rexaline

Today, 8:56 PM

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.

ACHV

3 minute read

32 Stocks Moving in Friday’s Pre-Market Session

By Lisa Levin

Today, 8:56 PM

Gainers Cyren Ltd. (NASDAQ: CYRN) rose 54.6% to $7.48 in pre-market trading after gaining around 119% on Thursday. The company recently announced a $12 million private placement.

BXRX

32 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 8:56 PM

On Thursday, 615 stocks hit new 52-week lows.

AAOI

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 8:56 PM

Gainers Rani Therapeutics Hldgs (NASDAQ:RANI) stock rose 7.36% to $35.0 during Wednesday's after-market session. The company's market cap stands at $690.0 million. As per the news, the Q3 earnings report came out 2 days ago.

ACOR

3 minute read

30 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 8:56 PM

Gainers RenovoRx, Inc. (NASDAQ: RNXT) rose 113% to $11.50 in pre-market trading. The company, on Tuesday evening, made a presentation on intra-arterial chemotherapy as a potential innovative treatment for pancreatic cancer.

AMPL

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 2, 2021

By Benzinga Insights

Today, 8:56 PM

1 minute read

Baird Initiates Coverage On Geron with Outperform Rating, Announces Price Target of $4

By Benzinga Newsdesk

Today, 8:56 PM

Baird analyst Joel Beatty initiates coverage on Geron (NASDAQ:GERN) with a Outperform rating and announces Price Target of $4.

GERN

1 minute read

Geron Shares Up ~7% After Hours On Heavy Volume As Hearing Baird Initiated Coverage On Stock With Outperform Rating, $4 Price Target

By Benzinga Newsdesk

Today, 8:56 PM

-TradeXchange

GERN

2 minute read

FDA
News

Geron Says Enters Into New Innovative Licensing And Access Pathway In U.K. For Imetelstat

By Benzinga Newsdesk

Today, 8:56 PM

Geron Corporation (NASDAQ:GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that imetelstat, the Company's first in class telomerase inhibitor, has been granted an Innovation Passport, which is the first prescribed entry point to t

GERN